<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072730</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE Nr. BA00421</org_study_id>
    <nct_id>NCT05072730</nct_id>
  </id_info>
  <brief_title>ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2</brief_title>
  <acronym>ISAR-CALC2</acronym>
  <official_title>Super High-Pressure Balloon Versus Intravascular Lithotripsy for Severely Calcified Coronary Lesions: The ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions (ISAR-CALC) 2 Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>SIS Medical AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ISAR-CALC 2 trial is an investigator-initiated, prospective, randomized, multicenter,&#xD;
      assessors-blind, open-label other clinical investigation. The objective of this trial is to&#xD;
      investigate final angiographic minimal lumen diameter (MLD) following a strategy of super&#xD;
      high-pressure balloon (OPN NC) versus intravascular lithotripsy (IVL) for drug-eluting stent&#xD;
      (DES) implantation in severely calcified coronary lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed information is provided elsewhere.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2022</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final angiographic minimal lumen diameter</measure>
    <time_frame>Intraprocedural.</time_frame>
    <description>The primary outcome measure of the trial is the final angiographic minimal lumen diameter as assessed by angiographic core laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic Success</measure>
    <time_frame>Intraprocedural.</time_frame>
    <description>Defined as target lesion residual angiographic stenosis &lt; 30% in the presence of Thrombolysis in Myocardial Infarction (TIMI) 3 flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>During index hospitalization, assessed up to 30 days.</time_frame>
    <description>Defined as angiographic success without the occurrence of major adverse cardiac event (MACE), a composite of cardiac death, target-vessel related MI and repeat target-vessel revascularization, during index hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strategy Success</measure>
    <time_frame>Intraprocedural.</time_frame>
    <description>Defined as procedural success using the assigned study device and DES, without requirement for additional devices for lesion preparation; i.e. rotational atherectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute lumen gain</measure>
    <time_frame>Intraprocedural.</time_frame>
    <description>Defined as minimal lumen diameter (MLD) after balloon angioplasty with the assigned study devices minus baseline MLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complementary lesion preparation</measure>
    <time_frame>Intraprocedural.</time_frame>
    <description>Need for complementary lesion preparation with rotational atherectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE rates</measure>
    <time_frame>30 days.</time_frame>
    <description>Occurrence of major adverse cardiac event (MACE) up to 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent expansion as assessed by OCT imaging.</measure>
    <time_frame>Intraprocedural.</time_frame>
    <description>Stent expansion index, defined as minimum stent area divided by mean reference lumen area assessed with OCT imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analysis</measure>
    <time_frame>Intraprocedural.</time_frame>
    <description>Cost-effectiveness analysis of OPN versus IVL in severely calcified coronary lesions treated with DES implantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Calcified Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Super high-pressure balloon (OPN NC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with a Super High Pressure percutaneous transluminal coronary angioplasty (PTCA) Balloon (OPN NC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravascular lithotripsy (IVL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with intravascular lithotripsy (IVL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Super High Pressure Balloon (OPN NC)</intervention_name>
    <description>Strategy of super high-pressure balloon angioplasty after unsuccessful lesion preparation with conventional NC balloon angioplasty.&#xD;
Optical coherence tomography (OCT) imaging will be performed after lesion preparation with OPN balloon. Optional additional pre-dilatation with OPN/standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with OPN balloon or standard NC balloon is permitted at the operator´s discretion.</description>
    <arm_group_label>Super high-pressure balloon (OPN NC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravascular lithotripsy (IVL)</intervention_name>
    <description>Strategy of IVL after unsuccessful lesion preparation with conventional NC balloon angioplasty.&#xD;
Optical coherence tomography (OCT) imaging will be performed after lesion preparation with IVL balloon. Optional additional pre-dilatation with standard NC balloon is permitted at the operator´s discretion. Following lesion preparation, stenting will be performed in the same setting using a latest-generation everolimus-eluting stent (XIENCE; Abbott Vascular, Chicago, IL, USA). Optional post-dilatation with standard NC balloon is permitted at the operator´s discretion.</description>
    <arm_group_label>Intravascular lithotripsy (IVL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above 18 years and able to give consent&#xD;
&#xD;
          -  Persistent angina despite medical therapy and/or evidence of inducible ischemia&#xD;
&#xD;
          -  De-novo lesion in a native coronary artery&#xD;
&#xD;
          -  Target reference vessel diameter or intended stent diameter ≥2.50 or ≤4.00 mm by&#xD;
             visual estimation&#xD;
&#xD;
          -  Severe calcification of the target lesion as determined by visual estimation at&#xD;
             coronary angiography&#xD;
&#xD;
          -  Unsuccessful lesion preparation with standard non-compliant balloon (&lt; 30% reduction&#xD;
             of baseline diameter stenosis at maximal pressure)&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target lesion is located in a coronary artery bypass graft&#xD;
&#xD;
          -  Target lesion is an in-stent restenosis&#xD;
&#xD;
          -  Target lesion is a chronic total occlusion&#xD;
&#xD;
          -  Target vessel thrombus&#xD;
&#xD;
          -  Limited long-term prognosis due to other comorbid conditions with life expectancy &lt;12&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Cassese, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Rheude, MD</last_name>
    <phone>+49 89 1218 2985</phone>
    <email>rheude@dhm.mhn.de</email>
  </overall_contact>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>March 28, 2022</last_update_submitted>
  <last_update_submitted_qc>March 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

